Skip to main content

Table 2 Clinical, serological, and pharmacological treatments in patients with systemic lupus erythematosus: correlation with adenosine A2A receptor affinity and density

From: A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus

  Patients (n) K d (nM) p Value Bmax (fmol/mg of protein) p Value
Disease activity patterns
 CQD/CAD 46/18 1.96 ± 1.19/1.77 ± 0.89 NS 141.6 ± 48.9/76 ± 28.6 < 0.0001
Organ involvement
 Renal, yes/no 13/67 1.33 ± 0.59/1.94 ± 1.15 0.06 114 ± 45.05/120.8 ± 52.3 NS
 Neuropsychiatric, yes/no 20/60 1.73 ± 0.81/1.88 ± 1.18 NS 103.85 ± 48.2/125 ± 51.2 NS
 Articular, yes/no 46/34 1.79 ± 1.22/1.9 ± 0.9 NS 110.85 ± 49.3/131.8 ± 51.5 0.06
 Cutaneous, yes/no 25/55 1.46 ± 0.71/1.89 ± 1.2 NS 105.60 ± 43.9/123.8 ± 53.7 NS
 Hematological, yes/no 41/39 1.70 ± 0.89/1.98 ± 1.28 NS 116.85 ± 47.8/123.6 ± 54.5 NS
 Serositis, yes/no 21/59 1.60 ± 1.3/1.9 ± 0.9 NS 92.86 ± 38.7/129.2 ± 51.6 0.0043
Serological parameters
 aCL, yes/no 22/58 1.91 ± 1.01/1.81 ± 1.14 NS 134.04 ± 52.55/114.27 ± 47.3 NS
 Anti-β2-GPI, yes/no 9/71 1.59 ± 0.46/1.87 ± 1.15 NS 116.11 ± 53.15/120.2 ± 51.1 NS
 LA, yes/no 28/52 1.92 ± 1.20/1.8 ± 1.05 NS 109.03 ± 51.60/125.5 ± 50.2 NS
 ENA, yes/no 58/22 1.92 ± 1.15/1.77 ± 1.07 NS 114,5 ± 47.34/123.1 ± 53.52 NS
 Hypocomplementemia, yes/no 53/27 1.57 ± 0.78/2.15 ± 1.32 NS 97.88 ± 39.25/145.08 ± 51.78 < 0.0001
 Anti-dsDNA, yes/no 41/39 1.65 ± 1.01/2.31 ± 1.18 0.008 106.26 ± 48.42/153.04 ± 41.76 < 0.0001
Treatments
 Corticosteroids, 2.5 up to 12.5 mg/day, yes/no 67/13 1.83 ± 1.17/1.88 ± 0.63 NS 113.12 ± 50.30/153.69 ± 41.47 0.0078
 Hydroxychloroquine, 200 mg/day, yes/no 48/32 1.93 ± 1.07/1.69 ± 1.13 NS 126.89 ± 51.09/108.93 ± 49.72 NS
 Immunosuppressants or induction therapy, yes/no 25/55 1.98 ± 1.19/1.54 ± 0.8 NS 124.31 ± 48.04/110.15 ± 56.46 NS
 Anticoagulants, yes/no 11/69 2.01 ± 1.47/1.81 ± 1.04 NS 128.91 ± 64.01/128.91 ± 64 NS
 Antiaggregants, yes/no 33/47 2.03 ± 1.24/1.7 ± 0.97 NS 123.39 ± 50.61117.13 ± 51.66 NS
  1. Abbreviations: aCL anticardiolipin antibodies, anti-β 2 -GPI anti-β2-glycoprotein I, CAD chronic active disease, CQD clinical quiescent disease, dsDNA double-stranded DNA, ENA extractable nuclear antigen antibodies, LA lupus anticoagulant, NS not significant
  2. Analysis was carried out using unpaired t tests.